Literature DB >> 25535459

Propranolol therapy for infantile hemangioma is less toxic but longer in duration than corticosteroid therapy.

Kathryn Sawa1, Arjang Yazdani1, Michael J Rieder2, Guido Filler3.   

Abstract

BACKGROUND: Infantile hemangioma is the most common benign, self-limiting tumour of childhood. Treatment is reserved for hemangiomas that obstruct vital structures or cause significant disfigurement. Traditionally, corticosteroids have been the medical treatment of choice. Since 2008, however, propranolol has been rapidly adopted as an effective pharmacological treatment for infantile hemangioma. Published data regarding the long-term side effects of propranolol are currently lacking.
OBJECTIVE: To describe the long-term effects of propranolol and corticosteroids on anthropometric measurements (height, body mass index [BMI]) and blood pressure in children.
METHODS: A prospective database analysis of all infantile hemangioma patient visits to the pediatric vascular abnormality clinic at the authors' institution between October 2007 and February 2012 was performed. Anthropometric measures (height and BMI) and blood pressure were analyzed.
RESULTS: A total of 290 visits (119 patients) to the pediatric vascular abnormality clinic were reviewed. Of these, 18 patients received medical treatment and their anthropometry was analyzed. BMI percentile increased significantly in patients treated with corticosteroids (P=0.0039). Corticosteroid treatment also resulted in a significant decrease in height percentile (P=0.0078). Anthropometric measures did not cross percentiles in children treated with propranolol. A significant decrease in systolic blood pressure was noted in the propranolol group (P=0.03), but no hypotensive values were recorded. Median treatment duration was significantly longer when patients received propranolol (372 versus 133 days; P=0.0033).
CONCLUSION: Propranolol for the treatment of infantile vascular abnormalities does not share the unfavourable effects on patient anthropometry that corticosteroids exhibit; however, a longer duration of therapy is required.

Entities:  

Keywords:  Hemangioma; Multidisciplinary clinic, Prednisolone; Prednisone; Propranolol; Surgical treatment

Year:  2014        PMID: 25535459      PMCID: PMC4271750          DOI: 10.4172/plastic-surgery.1000892

Source DB:  PubMed          Journal:  Plast Surg (Oakv)        ISSN: 2292-5503            Impact factor:   0.947


  16 in total

1.  Effects of prolonged cortisone therapy on the statural growth, skeletal maturation and metabolic status of children.

Authors:  F M BLODGETT; L BURGIN; D IEZZONI; D GRIBETZ; N B TALBOT
Journal:  N Engl J Med       Date:  1956-04-05       Impact factor: 91.245

2.  Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA.

Authors:  Ilona J Frieden; Anita N Haggstrom; Beth A Drolet; Anthony J Mancini; Sheila Fallon Friedlander; Laurence Boon; Sarah L Chamlin; Eulalia Baselga; Maria C Garzon; Amy J Nopper; Dawn H Siegel; Erin W Mathes; Deborah S Goddard; Joyce Bischoff; Paula E North; Nancy B Esterly
Journal:  Pediatr Dermatol       Date:  2005 Sep-Oct       Impact factor: 1.588

3.  Steroid therapy of a proliferating hemangioma: histochemical and molecular changes.

Authors:  Q Hasan; S T Tan; J Gush; S G Peters; P F Davis
Journal:  Pediatrics       Date:  2000-01       Impact factor: 7.124

4.  Complications of systemic corticosteroid therapy for problematic hemangioma.

Authors:  L M Boon; D M MacDonald; J B Mulliken
Journal:  Plast Reconstr Surg       Date:  1999-11       Impact factor: 4.730

5.  Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation.

Authors:  M L Bennett; A B Fleischer; S L Chamlin; I J Frieden
Journal:  Arch Dermatol       Date:  2001-09

6.  Multidisciplinary Versus One-on-One Setting: A Qualitative Study of Clinicians' Perceptions of Their Relationship With Patients With Prostate Cancer.

Authors:  Lara Bellardita; Simona Donegani; Andrea L Spatuzzi; Riccardo Valdagni
Journal:  J Oncol Pract       Date:  2011-01       Impact factor: 3.840

7.  A randomized controlled trial of propranolol for infantile hemangiomas.

Authors:  Marcia Hogeling; Susan Adams; Orli Wargon
Journal:  Pediatrics       Date:  2011-07-25       Impact factor: 7.124

8.  Beta-blockers for the treatment of problematic hemangiomas.

Authors:  Vishal K Sharma; Frankie Og Fraulin; Danielle O Dumestre; Lori Walker; A Robertson Harrop
Journal:  Can J Plast Surg       Date:  2013

9.  Propranolol for severe infantile hemangiomas: follow-up report.

Authors:  Véronique Sans; Eric Dumas de la Roque; Jérôme Berge; Nicolas Grenier; Franck Boralevi; Juliette Mazereeuw-Hautier; Dan Lipsker; Elisabeth Dupuis; Khaled Ezzedine; Pierre Vergnes; Alain Taïeb; Christine Léauté-Labrèze
Journal:  Pediatrics       Date:  2009-08-10       Impact factor: 7.124

10.  Bone histology in steroid-treated children with non-azotemic nephrotic syndrome.

Authors:  Michael Freundlich; Michael Jofe; William G Goodman; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2004-02-26       Impact factor: 3.714

View more
  1 in total

1.  The effectiveness of oral propranolol for infantile hemangioma on the head and neck region: A case series.

Authors:  Prasetyanugraheni Kreshanti; Nandya Titania Putri; Valencia Jane Martin; Chaula Luthfia Sukasah
Journal:  Int J Surg Case Rep       Date:  2021-06-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.